[EO-02] Platform Session 02：Neuromuscular Disorders 2

[EO-011] Early immunologic responses to the mRNA SARS—CoV—2 vaccine in patients with neuromuscular disorders

Hideyuki Iwayama¹，Naoko Ishihara²，Kohei Kawahara¹，Yuta Madokoro³，Yasuko Togawa⁴，Kanji Muramatsu⁴，Ayuka Murakami^5,6，Satoshi Kuru⁵，Toshiyuki Kumagai⁷，Wataru Ohahi⁸，Kengo Nanya⁹，Shinji Hasegawa¹⁰，Masahisa Katsuno¹⁰，Akihisa Okumura¹ (1. Department of Pediatrics, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan，2. Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Aichi, Japan，3. Department of Neurology, Nagoya City University Hospital, Nagoya, Aichi, Japan，4. Department of Pediatrics, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan，5. Department of Neurology, National Hospital Organization Suzuka Hospital, Suzuka, Mie, Japan，6. Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan，7. Department of Pediatric Neurology, Aichi Prefectural Colony Central Hospital, Kasugai；Kuma Home Medical Care Clinic, Nagoya, Aichi, Japan，8. Division of Biostatistics, Clinical Research Center, Aichi Medical University School of Medicine，9. Clinical Laboratory, Nagoya Memorial Hospital, Nagoya, Aichi, Japan，10. Department of Pediatrics, Nagoya Memorial Hospital, Nagoya, Aichi, Japan)